K. Aogi

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

Kenji Tamura, Chikako Shimizu, Takashi Hojo et al. · Annals of Oncology · 2010 · 180 citations

Breast Oncology, Oncology, Metastatic Settings +9

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry

Naoki Niikura, Ai Tomotaki, Hiroaki Miyata et al. · Annals of Oncology · 2015 · 180 citations

Breast Oncology, Medicine, Pharmacology +10

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

K. Aogi, Hiroji Iwata, Norikazu Masuda et al. · Annals of Oncology · 2011 · 122 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +8

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

Masakazu Toi, Hiroji Iwata, Yasuhiro Fujiwara et al. · British Journal of Cancer · 2009 · 93 citations · Full text

Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates.

K. Aogi, K Kitahara, I Buley et al. · PubMed · 1998 · 67 citations

Telomerase Enzyme, Cell Division, Clinical Samples +10